IsoPlexis partners with Columbia for vaccine development

By The Science Advisory Board staff writers

August 14, 2020 -- IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome immune profiling platform will be used to study cellular drivers of durable and protective immune response to the virus.

IsoPlexis' T cell and other immune cell polyfunctional cytokine responses have been able to predict a variety of responses in human and mice studies throughout cancer immunology and infectious disease. Also, Moriya Tsuji, a professor of medicine at Columbia, has published vaccine studies of malaria and also in oncology that used IsoPlexis' single-cell functional proteomics platform.

Columbia and IsoPlexis plan to detect and discover critical components in the overall cellular response to COVID-19, which can then be used to create therapies.

Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...
U.S. to pay $1.5B for Moderna's COVID-19 vaccine
The U.S. government awarded a maximum $1.525 billion contract to Moderna to secure 100 million doses of its messenger RNA COVID-19 vaccine.
Biosimulation can mitigate risk of COVID-19 drug development
Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation...
COVID-19 vaccine based on peptide nanofibers shows promise
A new technology platform using self-assembling peptide nanofibers tagged with antibodies can be an effective SARS-CoV-2 vaccine, according to a proof-of-concept...
New COVID-19 vaccine candidate leverages earlier research
Could vaccine platforms developed for previous coronaviruses be converted to address the current COVID-19 pandemic? An August 5 report in Nature...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter